Instead, they launched the most aggressive product imaginable, forced the FDA into a public response, and that response covers all GLP-1 APIs, including the injectables they were happily selling without scrutiny
Food industry executives are calling up pharma bosses to express their fears and ask for advice about succeeding in the post-Ozempic food era
Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials
Some beneficial bacteria produce metabolites that may stimulate L-cells
To test whether the regulation of CYP8B1 by T3 would have any effect on BA composition, we performed UFLC-Triple-time of flight/MS-based metabolite profiling to quantitate the BA levels and found that the percentage of 12-hydroxylated (12-OH) BAs was reduced, while the proportion of non-12-hydroxylated (non-12-OH) BAs was increased in the gallbladder bile, ileum, liver, serum, and urine after five days of T3 treatment in MMI mice (Fig
GLP-1a: Going beyond Traditional Use